The effect of treatment strategy on survival. (A) Patients who received stem cell transplantation (SCT) as first therapy (n = 2) or in first response (n = 6) had the most favorable outcome, with actuarial survival of 73% at a median survivor follow-up of 31 months (range, 6-131 months). Survival was similar between patients receiving AML induction (median, 6 months) and low-intensity therapy (median, 7 months). Patients receiving supportive care only had a median survival of 6 weeks. (B) Survival analysis comparing SCT as first therapy or in first response (n = 8) with patients achieving complete response (CR) plus or minus blood recovery (CRi) who did not proceed to early SCT (n = 13), and patients who received antileukemia therapy but who did not achieve a CR/CRi (n = 32). Median survival was not reached, 13 months and 4 months, respectively.